Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has issued an announcement.
SanBio Co., Ltd. announced a deviation from its consolidated earnings forecast for the fiscal year ending January 31, 2025, with actual results showing a larger-than-expected ordinary loss. This was primarily due to foreign exchange gains on foreign currency loans and stock issuance expenses. The net loss attributable to owners was also higher than projected due to gains on reversal of share subscription rights and deferred tax liabilities. These results may impact the company’s financial stability and investor confidence.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of regenerative cell medicines. The company aims to address unmet medical needs in the field of neurological disorders.
YTD Price Performance: 40.86%
Average Trading Volume: 1,013
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $558.9M
Learn more about 4592 stock on TipRanks’ Stock Analysis page.